APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Brief description of study
If you or your child has been diagnosed with recurrent or refractory solid tumors, you or your child may qualify to participate in a phase 2 study of a drug called tazemetostat in children with recurrent or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS tumors). The goal of this study is to find out what effects, good and or bad, the drug tazemetostat has on your tumor or type of cancer.
Clinical Study Identifier: s17-01131
ClinicalTrials.gov Identifier: NCT03213665
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
